Cisapride for gastro-oesophageal reflux and peptic oesophagitis

S CUCCHIARA, A STAiano, C CAPOZZI, C DI LORENZO, A BOCCHIERI, AND S AURICCHIO

Clinical Pediatrics, Second School of Medicine, University of Naples, Naples, Italy

SUMMARY Twenty children (age range 75 days–47 months) with reflux oesophagitis entered a random double blind trial in which they received either Cisapride (Janssen Pharmaceutical Ltd), a new prokinetic agent, or an identical placebo syrup. Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry. Oesophagitis was assessed in all patients by histological examination of mucosal specimens taken during oesophagogastrroduodenoscopy. Manometry, pH test, and endoscopy with biopsy examination were repeated at the end of the treatment period. Seventeen patients completed the trial, eight of whom were taking the drug and nine the placebo. Mean total clinical score and post-prandial reflux time (%) of reflux) significantly improved in patients in the group given Cisapride but not in the group given placebo. Furthermore, there was a significant improvement of the histological oesophagitis score only in the children in the group given Cisapride, whereas placebo was ineffective. It is concluded that Cisapride is a useful agent both for the relief of symptoms of gastro-oesophageal reflux and for the healing of peptic oesophagitis in infancy.

In the past few years there have been a number of studies on gastro-oesophageal reflux in children.1–3 Interest has been concentrated mainly on the clinical presentation and on providing reliable diagnostic tests. A few studies, however, have been directed towards assessing the therapeutic approach of the disease. Recent trials have shown that children with reflux can be successfully treated with betahexanechlor chloride.4–7 A cholinergic drug that stimulates intestinal smooth muscle contraction.8 In a controlled trial antacids as well as cimetidine proved to be effective for the relief of both symptoms and oesophagitis.9 Finally, a recent open study showed that domperidone, a new prokinetic agent, induced a significant improvement both in symptoms of reflux and in some gastro-oesophageal motility variables.10

In only one study, however, was the trial designed in a double blind fashion.4 As gastro-oesophageal reflux has a favourable natural history in children,11 double blind controlled trials would seem to be advisable to assess the true place of medical treatment of reflux in children.

Cisapride (R 51 619, Janssen Pharmaceutical Ltd) is a new prokinetic drug that stimulates smooth muscle cell contraction of the gastrointestinal tract.12 This prompted us to investigate the effect of oral Cisapride compared with placebo in the treatment of children with symptomatic gastro-oesophageal reflux and peptic oesophagitis.

Patients and methods

Twenty patients, nine boys and 11 girls, aged 75 days–47 months, with a diagnosis of gastro-oesophageal reflux and oesophagitis, were entered into a double blind trial to compare Cisapride syrup (1 mg/ml) at a dose of 0.3 mg/kg three times a day before meals with placebo syrup, which was identical to Cisapride in taste and appearance, taken at the same dose, over eight weeks. In each patient diagnosis of gastro-oesophageal reflux was based on pH-metric demonstration of acid reflux. Fibreoptic endoscopy and biopsy examination revealed oesophagitis in all 20 patients. Infectious, neurologic, metabolic, and renal disorders were carefully excluded. Abnormalities of the oesophagus, stomach, and duodenum were excluded by upper intestinal x ray examination. Parents gave informed consent and the study was approved by the ethical committee of our faculty.

Gastro-oesophageal reflux was detected by a five hour pH study, performed after ingestion of apple juice (15–20 cc/kg), with a pH of 4. A small flexible
electrode (MI 506, Microelectrodes Inc, London-
derry, New Hampshire, United States of America),
calibrated with buffers at pH levels of 7.0 and 4.0,
was introduced nasally and located at 87% of the
distance from the nares to the lower oesophageal
sphincter previously determined by manometry.
Gastro-oesophageal reflux was defined as a fall in
intra-oesophageal pH below 4 for at least 20
seconds.
Manometry was performed by a triple lumen
catheter with side recording orifices spaced 2.5 cm
apart and perfused with bubble free water at a low
compliance infusion system (Arndorfer, Med Spec
Co, Greendale, Wisconsin, USA). The probe was
initially located into the stomach and subsequently
moved across the lower oesophageal sphincter
0.5 cm at a time, remaining at each station long
enough to obtain a stable pressure recording.
Lower oesophageal sphincter pressure was deter-
mined as mean pressure of the three orifices, with
the gastric pressure as zero reference, taking the
mid-respiratory value. Motor activity of the distal
oesophagus was recorded by placing the distal side
hole of the catheter immediately proximal to the
lower oesophageal sphincter. Oesophageal waves
were elicited by administering 2 ml of 5% dextrose.
Only waves preceded by at least 30 seconds of silent
motor activity in the oesophagus were taken into
account. Amplitude of peristalsis (mm Hg) was
measured by subtracting the mean resting
oesophageal pressure from the peak of the waves.
Both oesophageal manometry and pH study were
performed during the same session after a two to
three hour fast without sedation. Patients with
diagnosis of reflux underwent upper endoscopy with
a small fibreoptic endoscope (GIF PX Olympus).
Mucosal erythema or oedema were not con-
sidered to be reliable findings of oesophagitis.
Endoscopic lesions, such as friability, exudate,
erosions, or ulcerations, were considered to be
important markers of oesophagitis. During
endoscopy, biopsy specimens were taken from the
oesophageal mucosa, irrespective of its appearance,
and examined by a histopathologist, who was
unaware of the endoscopic findings. The degree of
oesophagitis was histologically defined as ‘mild’ if
there was basal cell hyperplasia and extension of the
papillae, ‘moderate’ if there was also an increased
cellularity of the lamina propria, and ‘severe’ if there
were also signs of mucosal ulcerations.
Blood counts, urinalysis, and determination of
serum transaminase and alkaline phosphatase activi-
ties, and bilirubin, creatinine, and urea concen-
trations were taken before randomisation to either
Cisapride or placebo. During the study, frequent
assessments were made of severity and frequency of
symptoms and drug use. Manometry, pH study,
endoscopy, and biopsy examination were repeated
within two days before the end of the trial for
comparison with pretreatment data. At completion
of the trial the patients were classified as ‘cured’ if
clinical, pH-metric, and histological variables had
normalised, ‘improved’ if at least one of these three
variables had ameliorated, and ‘unchanged’ or
‘worsened’ if no improvement or worsening was
observed, respectively. Throughout the trial,
parents were provided with diary cards to keep a
daily record of the symptoms and physical signs. A
scoring system was used to evaluate symptoms and
physical signs as well as oesophageal histology of the
patients (Table 1).

Data were analysed using either Student’s t test or
rank sum non-parametric tests. p Values <0.05
were considered significant.

Results

Three patients failed to complete the study and were
withdrawn, two because of febrile upper respira-
tory infections and one who failed to take the drug
continuously. Eight patients (age range 90 days–36
months) were treated with the drug and nine (age

<table>
<thead>
<tr>
<th>Table 1 Scoring system for symptoms or physical signs and for oesophagitis assessed by histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms or physical signs</td>
</tr>
<tr>
<td>Vomiting or regurgitation, or both (episodes/week)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Pneumonia or asthma (episodes/two months)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Apnoea (episodes/week)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Haematemesis (episodes/two months)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Heartburn, dysphagia (episodes/week)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Weight/height ratio (centile)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Oesophagitis (histology)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
range 75 days–47 months) with the placebo. The two groups were comparable for clinical and histological scores and for percentage of reflux time at the pH study.

Four patients on Cisapride and one on placebo were healed, two patients on Cisapride and one on placebo were considered to have improved, and nine children remained unchanged or worsened. Of these, two were in the Cisapride group and seven in the placebo group. As shown in Table 2, the post-treatment clinical score, percentage of reflux time, and histological score for oesophagitis were significantly better in the group treated with Cisapride but showed no change in the group treated with placebo. Furthermore, at the end of the trial amplitude of peristalsis was significantly increased only in the Cisapride group, whereas lower oesophageal sphincter pressure and mean duration of episodes of reflux showed no significant change in either groups. The percentage improvement from the pre-study baseline in clinical score and duration of reflux was higher in the Cisapride group than in the placebo group (Figure). There was a significant difference, however, only for the percentage change of the clinical score.

Four patients on Cisapride (three with moderate and one with mild oesophagitis before treatment) were totally healed. Two of the remaining four patients on Cisapride had severe oesophagitis at the beginning of the study, one of whom remained unchanged and one of whom improved. The other two patients on Cisapride had moderate oesophagitis, and again one remained unchanged and one improved.

Of the patients on placebo, one who initially had severe oesophagitis remained unchanged at the completion of the trial. Six had moderate oesophagitis at the start of the trial. Of these, three failed to improve, two had an improvement in the histological appearance, and one healed. Finally, two patients who had mild oesophagitis at the start of the trial remained unchanged at the end.

No significant changes occurred in the biochemical variables. No untoward clinical signs or symptoms were observed during the trial.

Discussion

Major advances have recently been made in under-

Table 2 Results obtained in 17 patients with gastro-oesophageal reflux after eight weeks of treatment with Cisapride or placebo. Results are given as mean (SD)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Cisapride</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before treatment</td>
<td>After treatment</td>
</tr>
<tr>
<td>Clinical score*</td>
<td>16-25 (7-1)</td>
<td>7-47 (7-05)</td>
</tr>
<tr>
<td>% Of reflux time*</td>
<td>25-68 (11-65)</td>
<td>11-83 (11-97)</td>
</tr>
<tr>
<td>Duration of episodes of gastro-oesophageal reflux (min)</td>
<td>4-28 (0-71)</td>
<td>4-12 (1-11)</td>
</tr>
<tr>
<td>Lower oesophageal sphincter pressure (mm Hg)</td>
<td>20-62 (7-53)</td>
<td>19-62 (4-62)</td>
</tr>
<tr>
<td>Peristalsis amplitude (mm Hg)</td>
<td>46-9 (15-7)</td>
<td>57-7 (11-9)</td>
</tr>
<tr>
<td>Histological score for oesophagitis</td>
<td>6-37 (1-92)</td>
<td>3-0 (3-58)</td>
</tr>
</tbody>
</table>

*No significant difference in the two groups of patients for the clinical and histological scores and percentage of reflux time before treatment. NS=Not significant.
Cisapride for gastro-oesophageal reflux and peptic oesophagitis

standing the physiopathological mechanisms of gastro-oesophageal reflux.\(^1\)\(^2\) There is evidence that the pathogenesis of reflux has many components, such as lower oesophageal sphincter incompetence, abnormal oesophageal peristalsis, delayed gastric emptying, and oesophageal mucosal damage from gastric content. Treatment of reflux might be directed, therefore, towards either counteracting upper gastrointestinal motor defects or altering the character of the gastric content available for reflux. Cisapride is a new prokinetic drug that facilitates release of acetylcholine from the myenteric plexus and has no dopamine blocking properties, and in vivo and in vitro studies have shown that it increases lower oesophageal sphincter pressure and amplitude of oesophageal peristalsis and improves gastric emptying (Gilbert RJ, Dodds WJ, Karhila PJ, Hogan WJ, Lipman S. Double-blind assessment of the effect of intravenous and oral Cisapride on oesophageal motor function. Abstract presented at First International Investigations Meeting on Cisapride, Brussels, December 1985.)\(^3\) For this reason, the drug has great potential in the treatment of gastro-oesophageal reflux.

The results of this trial indicate that Cisapride is more effective than placebo in the relief of symptoms of gastro-oesophageal reflux in children. Symptomatic control in patients treated with Cisapride was documented both by decreased duration of reflux time during the repeated pH test and by significant improvement in the oesophageal histological damage. No changes in the lower oesophageal sphincter pressure were noted between the results of manometry before and after treatment in the two groups. Although the children on Cisapride showed a slightly significant increase of oesophageal peristaltic amplitude compared with those on placebo, however, amplitude of peristalsis was not remarkably decreased before treatment in either groups. Moreover, basal mean values of lower oesophageal sphincter pressure in all our patients were not different from that of a normal paediatric population.\(^4\) This would suggest that patients included in the study as a whole had moderate reflux. Cisapride caused a significant reduction of the reflux time, whereas mean duration of reflux was unchanged. This finding was mainly due to a decreased frequency of episodes of reflux and implies that the drug might be more effective on the mechanisms related to the frequency of episodes of reflux, such as lower oesophageal sphincter pressure and gastric emptying. Cisapride has also been shown to improve gastric emptying: documentation of this effect is lacking in our study.

Cisapride was also more effective than placebo in improving histological changes of oesophagitis. Of the 17 patients included in the study, however, only three had severe oesophagitis; the remaining 14 had mild or moderate oesophagitis. The effectiveness of Cisapride in the treatment of more severe reflux oesophagitis remains to be proved.

The manometric findings, such as normal (or slightly decreased) pressure of peristalsis and lower oesophageal sphincter absence of non-specific oesophageal motor defects, and the prevailing moderate degree of oesophagitis, indicate that our group of selected patients was not seriously affected. It would be desirable, therefore, for future trials with Cisapride in children affected by gastro-oesophageal reflux to include more patients with severe reflux oesophagitis.

References


Correspondence to Dr S Cucchiara, Clinica Pediatrica, I. Facoltà di Medicina, Università di Napoli, Via S Paisini 5, 80131 Naples, Italy.

Received 9 December 1986

Downloaded from http://adc.bmj.com/ on June 20, 2017 - Published by group.bmj.com
Cisapride for gastro-oesophageal reflux and peptic oesophagitis.

S Cucchiara, A Staiano, C Capozzi, C Di Lorenzo, A Boccieri and S Auricchio

Arch Dis Child 1987 62: 454-457
doi: 10.1136/adc.62.5.454

Updated information and services can be found at:
http://adc.bmj.com/content/62/5/454

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/